Gastrointestinal Adverse Events of Bispecific Antibodies in Cancer: A Systematic Review and Proportional Meta-Analysis (ACG 2026) - Aug 29, 2026 - Abstract #P2567; Pres time: Oct 12, 2026; 10:30 AM - 04:15 PM; Location: Exhibit Halls A - D (Level 3); "Sensitivity analyses excluding studies with an 8-week blinatumomab exposure window (27.2%, 95% CI 18.1-37.4%) and mixed CTCAE version reporting (24.2%, 95% CI 14.2-35.9%) were consistent with the primary result...GPRC5D-directed oral toxicity could not be assessed because no talquetamab trials met inclusion criteria... Eight trials enrolling 870 participants across five bispecific antibody target classes were included. Any-grade diarrhea incidence was 25.4% (95% CI 16.4-35.6%; prediction interval [PI] 5.4-53.7%; I²=82.3%; tau²=0.013). Grade 3-4 diarrhea incidence was 1.0% (95% CI 0.0-4.5%; PI 0.0-9.3%; k=4, N=564)."
Adverse events • Bispecific • Retrospective data • Review • Oncology • Solid Tumor
|
|
Nayanika Tummala MD 1; Shankar Biswas MD 2; Puneet Gupta MD 3; Yashasvi Srivastava MBBS 4; Dhruv Gandhi MBBS MD 5
|